

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock Code: 1093)**

#### **VOLUNTARY ANNOUNCEMENT**

### **“SYHA1803” FOR THE TREATMENT OF INTRAHEPATIC CHOLANGIOCARCINOMA AND UROTHELIAL CARCINOMA WAS GRANTED CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “SYHA1803” developed by the Group (the “**Product**”) was granted approval by the National Medical Products Administration of China to conduct clinical trials in China. The Product has a number of patent applications in China and overseas.

The Product is a new type of small-molecule kinase inhibitor and currently there is no product of the same target available in the global market. The clinical indications approved for the Product include the treatment of intrahepatic cholangiocarcinoma and urothelial carcinoma. The pre-clinical studies indicated that the Product has an outstanding efficacy in respect of in vitro enzyme, cell activity and in vivo anti-tumor, and the characteristics of good safety and pharmacokinetics, providing a promising prospect of demonstrating good efficacy for the treatment of tumors in the clinical trials and bringing hope to those patients suffering from intrahepatic cholangiocarcinoma or urothelial carcinoma but without medication.

Given the favorable results in the non-clinical studies, the Group will endeavor to push forward with the clinical trials of the Product and strive to launch the Product as soon as possible for the sake of the patients in the world.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 12 April 2019

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Mr. ZHANG Cuilong, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*